US-based drugs company Cephalon has co-led the Y2bn ($24m) series E round for SymBio Pharmaceuticals, a Japan-based company treating blood disorders.
US-based drugs company Cephalon has co-led the Y2bn ($24m) series E round for SymBio Pharmaceuticals, a Japan-based company treating blood disorders.
Alongside Cephalon as co-lead was venture capital firm Jafco.
Fuminori Yoshida, executive president of SymBio, said: "I am extremely pleased that our two major shareholders continue to support our business at this juncture where SymBio needs capital to more aggressively expand into other Asia Pacific markets."
Currently, SymBio has four drug candidates under development in its pipeline, including one…
